Literature DB >> 3756068

Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.

T Inaba, R E Tyndale, W A Mahon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3756068      PMCID： PMC1401106          DOI： 10.1111/j.1365-2125.1986.tb05251.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.

Authors:  S V Otton; T Inaba; W Kalow
Journal:  Life Sci       Date:  1984-01-02       Impact factor: 5.037

Review 2.  Oxidation phenotype and the metabolism and action of beta-blockers.

Authors:  M S Lennard
Journal:  Klin Wochenschr       Date:  1985-04-01

3.  Comparative pharmacogenetics of sparteine and debrisoquine.

Authors:  T Inaba; A Vinks; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

4.  In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.

Authors:  T Inaba; M Jurima; W A Mahon; W Kalow
Journal:  Drug Metab Dispos       Date:  1985 Jul-Aug       Impact factor: 3.922

5.  Polymorphic drug oxidation in humans.

Authors:  M Eichelbaum
Journal:  Fed Proc       Date:  1984-05-15
  5 in total
  14 in total

1.  Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias.

Authors:  U M Birgersdotter; W Wong; J Turgeon; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

2.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.

Authors:  M D Nielsen; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

3.  Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.

Authors:  C Funck-Brentano; H K Kroemer; H Pavlou; R L Woosley; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

4.  Relevance of genetic polymorphism in drug metabolism in the development of new drugs.

Authors:  L P Balant; U Gundert-Remy; A R Boobis; C von Bahr
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.

Authors:  P Dalén; M Dahl; K Andersson; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

6.  Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer.

Authors:  J C Duche; C Joanne; J Barre; H de Cremoux; J C Dalphin; A Depierre; P Brochard; J P Tillement; P Bechtel
Journal:  Br J Clin Pharmacol       Date:  1991-05       Impact factor: 4.335

7.  Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.

Authors:  D Wu; S V Otton; B A Sproule; U Busto; T Inaba; W Kalow; E M Sellers
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

8.  Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.

Authors:  G Muralidharan; E M Hawes; G McKay; E D Korchinski; K K Midha
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.

Authors:  M R Shiran; J Chowdry; A Rostami-Hodjegan; S W Ellis; M S Lennard; M Z Iqbal; O Lagundoye; N Seivewright; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

10.  The effects of beta-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine.

Authors:  J Kallio; R Huupponen; M Seppälä; E Säkö; E Iisalo
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.